Thierry André

3 ta ish

Sorbonne University

1. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

   Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong +17

   MaqolaOAOchiq kirish20183 iqtibos

   ABIABI:AkademIndex/2026.other.241935

2. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

   Thierry André, Kai‐Keen Shiu, Tae Won Kim +18

   Maqola20203 iqtibos

   ABIABI:AkademIndex/2026.other.513933

3. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

   Michael J. Overman, Ray McDermott, Joseph L. Leach +13

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.241933